Amicus Therapeutics, Inc. (FOLD) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
114.88
+13% vs avg
5yr avg: 101.88
30Y Low92.7·High92.7
P/FCF
152.43
+4% vs avg
5yr avg: 147.11
30Y Low9.8·High147.1
P/B Ratio
↑
16.29
↓-15% vs avg
5yr avg: 19.16
30Y Low1.3·High28.7
ROE
↑
-11.6%
↓+83% vs avg
5yr avg: -68.9%
30Y Low-319%·High-9%
Debt/EBITDA
↓
11.52
↓-7% vs avg
5yr avg: 12.40
30Y Low11.5·High13.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FOLD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Amicus Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 152.4x P/FCF, roughly in line with the 5-year average of 147.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.5B | $4.4B | $2.9B | $4.2B | $3.5B | $3.1B | $6.0B | $2.3B | $1.8B | $2.2B | $668M |
| Enterprise Value | $4.8B | $4.7B | $3.1B | $4.4B | $3.8B | $3.3B | $6.3B | $2.4B | $2.0B | $2.3B | $635M |
| P/E Ratio → | -164.85 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.17 | 6.92 | 5.43 | 10.49 | 10.72 | 10.26 | 22.91 | 12.85 | 19.51 | 59.76 | 134.73 |
| P/B Ratio | 16.29 | 16.01 | 14.78 | 26.15 | 28.68 | 10.20 | 20.87 | 4.92 | 5.19 | 6.25 | 1.85 |
| P/FCF | 152.43 | 147.11 | — | — | — | — | — | — | — | — | — |
| P/OCF | 137.27 | 132.48 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FOLD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Amicus Therapeutics, Inc.'s enterprise value stands at 114.9x EBITDA, 13% above its 5-year average of 101.9x. The Healthcare sector median is 14.2x, placing the stock at a 709% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.35 | 5.86 | 10.98 | 11.64 | 10.90 | 23.98 | 13.22 | 22.16 | 62.88 | 128.16 |
| EV / EBITDA | 114.88 | 111.09 | 92.67 | — | — | — | — | — | — | — | — |
| EV / EBIT | 139.72 | 100.55 | 148.60 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 156.13 | — | — | — | — | — | — | — | — | — |
FOLD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Amicus Therapeutics, Inc. earns an operating margin of 5.4%. Operating margins have expanded from -19.3% to 5.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -11.6% indicates the company is currently destroying shareholder equity. ROIC of 5.3% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | 87.3% | 90.0% | 90.7% | 88.3% | 88.7% | 88.1% | 87.9% | 84.2% | 83.1% | 83.2% |
| Operating Margin | 5.4% | 5.4% | 4.7% | -19.3% | -64.4% | -67.6% | -94.7% | -166.8% | -360.3% | -1196.8% | -3668.6% |
| Net Profit Margin | -4.3% | -4.3% | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% | -195.6% | -382.5% | -769.0% | -4034.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.6% | -11.6% | -31.7% | -107.0% | -109.9% | -84.4% | -72.6% | -87.0% | -100.3% | -79.7% | -56.5% |
| ROA | -3.1% | -3.1% | -7.2% | -20.2% | -29.0% | -28.0% | -31.9% | -43.5% | -49.3% | -34.1% | -20.6% |
| ROIC | 5.3% | 5.3% | 4.8% | -14.8% | -34.3% | -29.0% | -33.4% | -40.4% | -46.8% | -83.3% | -42.1% |
| ROCE | 5.1% | 5.1% | 4.0% | -12.9% | -31.6% | -27.2% | -33.4% | -42.7% | -52.2% | -59.6% | -20.7% |
FOLD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Amicus Therapeutics, Inc. carries a Debt/EBITDA ratio of 11.5x, which is highly leveraged (258% above the sector average of 3.2x). Net debt stands at $269M ($483M total debt minus $214M cash). Interest coverage of just 1.0x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.76 | 1.76 | 2.29 | 2.78 | 3.67 | 1.43 | 1.54 | 0.44 | 0.94 | 0.47 | 0.43 |
| Debt / EBITDA | 11.52 | 11.52 | 13.27 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.98 | 1.18 | 1.24 | 2.46 | 0.63 | 0.97 | 0.14 | 0.71 | 0.33 | -0.09 |
| Net Debt / EBITDA | 6.42 | 6.42 | 6.88 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 9.02 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 1.00 | 1.00 | 0.42 | -1.99 | -5.52 | -6.44 | -11.23 | -17.86 | -14.58 | -25.05 | -36.75 |
FOLD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Amicus Therapeutics, Inc.'s current ratio of 2.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.88x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | 2.84 | 3.39 | 2.88 | 3.05 | 4.09 | 4.47 | 4.04 | 6.40 | 5.60 | 3.06 |
| Quick Ratio | 1.88 | 1.88 | 2.60 | 2.52 | 2.88 | 3.90 | 4.32 | 3.93 | 6.30 | 5.53 | 3.03 |
| Cash Ratio | 1.23 | 1.23 | 1.68 | 1.71 | 2.11 | 3.31 | 3.73 | 3.51 | 5.85 | 5.12 | 2.98 |
| Asset Turnover | — | 0.67 | 0.67 | 0.51 | 0.45 | 0.34 | 0.29 | 0.21 | 0.12 | 0.06 | 0.00 |
| Inventory Turnover | 0.35 | 0.35 | 0.45 | 0.63 | 1.62 | 1.29 | 1.59 | 1.56 | 1.72 | 1.35 | 0.24 |
| Days Sales Outstanding | — | 66.36 | 69.85 | 80.09 | 73.39 | 62.93 | 65.65 | 66.66 | 87.85 | 93.54 | 96.00 |
FOLD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Amicus Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.7% | 0.7% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% |
| Shares Outstanding | — | $308M | $304M | $295M | $289M | $271M | $259M | $240M | $186M | $153M | $134M |
Peer Comparison
Compare FOLD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FOLDYou | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $11B | 31.1 | 16.4 | 14.8 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 KRYS | $10B | 50.2 | 57.4 | 53.6 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $7B | 10.4 | 7.0 | 9.6 | 95.9% | 49.5% | — | — | 0.5 |
 LGND | $5B | 42.8 | 68.3 | 107.4 | 97.5% | 17.6% | 13.5% | 3.4% | 5.6 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.4 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
FOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
What is Amicus Therapeutics, Inc.'s P/E ratio?
Amicus Therapeutics, Inc.'s current P/E ratio is -164.8x. This places it at the 50th percentile of its historical range.
What is Amicus Therapeutics, Inc.'s EV/EBITDA?
Amicus Therapeutics, Inc.'s current EV/EBITDA is 114.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 92.7x.
What is Amicus Therapeutics, Inc.'s ROE?
Amicus Therapeutics, Inc.'s return on equity (ROE) is -11.6%. The historical average is -85.8%.
Is FOLD stock overvalued?
Based on historical data, Amicus Therapeutics, Inc. is trading at a P/E of -164.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Amicus Therapeutics, Inc.'s profit margins?
Amicus Therapeutics, Inc. has 87.3% gross margin and 5.4% operating margin.
How much debt does Amicus Therapeutics, Inc. have?
Amicus Therapeutics, Inc.'s Debt/EBITDA ratio is 11.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.